Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of NM-101 in Healthy Volunteers and MSA Patients
NCT06934941Phase 1Recruiting
- Sponsor
- Neuramedy
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple system atrophy (MSA) comparing NM-101 with Placebo (2 arms). Primary endpoint: Pharmacokinetic profile of NM-101 at Week 12. Started Nov 2024; status: recruiting.
02
Drugs
tomaralimab
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06934941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934941.